AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN
Press Release AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN • AVB-101 Biomarker Data Readout Expected in 2026 • Clinical Milestone Shared at AFTD Annual Caregiver Conference LONDON — MAY 1, 2025 —...
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
Press Release Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications Astellas receives an exclusive option to license AVB-101, an investigational, AAV-based gene therapy...